Durham, NC, United States
Durham, NC, United States

Time filter

Source Type

PMR estimates that kits for DNA and RNA sample preparation would account for around 60% market share in 2017. However, this product type segment is expected to witness a slight decline in its market share by 2025-end. Although kits will experience a decline in their market share, they are estimated to hold the largest market share in the global DNA and RNA sample preparation market during the forecast period. Workstations are expected to exhibit the fastest growth at 5.8% CAGR through 2025. The global DNA and RNA sample preparation market is projected to register a steady growth at 5.5% CAGR during the forecast period. The US$ 1,293.6 Mn market is estimated to reach US$ 2,090.2 Mn through 2025. Investment in basic research, particularly by academic & research institutes, since past several years have led to solid understanding of fundamental pathways. Through this, various proteins implicated in disease development are either up-regulated or down-regulated. In addition, growing requests by researchers for complex products is an evidence of improvement in understanding basic pathways and discovering new pathways. These factors lead to greater knowledge of cellular pathways, which in turn are estimated to fuel the demand for DNA and RNA sample preparation in the near future. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3211 Technological advancements in nucleic acid preparation processes have driven a greater demand for high quality kits, reagents, and associated products. Technological advancements in the methods of DNA and RNA sample preparation, global agreement between leading research institutes for boosting research activities in molecular biology field, soaring demand for modern extraction techniques, and technological advancements in analytical instruments are some major factors driving the market growth. However, increasing inclination of preferences for premium products, owing to their higher quality as compared to standard reagents and products, is expected to restrain the growth of the global DNA and RNA sample preparation market. Hospitals to be Second-most Lucrative End User by 2025-End Academic and research institutes are expected to be the most lucrative end user in the global DNA and RNA sample preparation market through 2025. This segment is expected to exhibit 5.9% CAGR during the forecast period. Hospitals are expected to be the second most lucrative end user segment in the overall market. Based on applications, research applications are expected to remain dominant in the global DNA and RNA sample preparation market during the forecast period. Clinical testing, following research applications, are expected to exhibit 5.4% CAGR through 2025. North America is estimated to be the largest region for DNA and RNA sample preparation market, and is expected to account for more than 40% market share by 2025 end. Although Europe is expected to be the second-most lucrative region for the market, Asia Pacific is estimated to exhibit a comparatively faster growth during the forecast period. Key players in the global DNA and RNA sample preparation market include Agilent Technologies, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma-Aldrich Corporation, Tecan Group AG, and Thermo Fischer Scientific, Inc. DNA & RNA Sample Preparation Market Report 2017-2025 is available for $4900 (Single User License) @ http://www.persistencemarketresearch.com/checkout/3069 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


PMR estimates that kits for DNA and RNA sample preparation would account for around 60% market share in 2017. However, this product type segment is expected to witness a slight decline in its market share by 2025-end. Although kits will experience a decline in their market share, they are estimated to hold the largest market share in the global DNA and RNA sample preparation market during the forecast period. Workstations are expected to exhibit the fastest growth at 5.8% CAGR through 2025. The global DNA and RNA sample preparation market is projected to register a steady growth at 5.5% CAGR during the forecast period. The US$ 1,293.6 Mn market is estimated to reach US$ 2,090.2 Mn through 2025. Investment in basic research, particularly by academic & research institutes, since past several years have led to solid understanding of fundamental pathways. Through this, various proteins implicated in disease development are either up-regulated or down-regulated. In addition, growing requests by researchers for complex products is an evidence of improvement in understanding basic pathways and discovering new pathways. These factors lead to greater knowledge of cellular pathways, which in turn are estimated to fuel the demand for DNA and RNA sample preparation in the near future. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3211 Technological advancements in nucleic acid preparation processes have driven a greater demand for high quality kits, reagents, and associated products. Technological advancements in the methods of DNA and RNA sample preparation, global agreement between leading research institutes for boosting research activities in molecular biology field, soaring demand for modern extraction techniques, and technological advancements in analytical instruments are some major factors driving the market growth. However, increasing inclination of preferences for premium products, owing to their higher quality as compared to standard reagents and products, is expected to restrain the growth of the global DNA and RNA sample preparation market. Hospitals to be Second-most Lucrative End User by 2025-End Academic and research institutes are expected to be the most lucrative end user in the global DNA and RNA sample preparation market through 2025. This segment is expected to exhibit 5.9% CAGR during the forecast period. Hospitals are expected to be the second most lucrative end user segment in the overall market. Based on applications, research applications are expected to remain dominant in the global DNA and RNA sample preparation market during the forecast period. Clinical testing, following research applications, are expected to exhibit 5.4% CAGR through 2025. North America is estimated to be the largest region for DNA and RNA sample preparation market, and is expected to account for more than 40% market share by 2025 end. Although Europe is expected to be the second-most lucrative region for the market, Asia Pacific is estimated to exhibit a comparatively faster growth during the forecast period. Key players in the global DNA and RNA sample preparation market include Agilent Technologies, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma-Aldrich Corporation, Tecan Group AG, and Thermo Fischer Scientific, Inc. DNA & RNA Sample Preparation Market Report 2017-2025 is available for $4900 (Single User License) @ http://www.persistencemarketresearch.com/checkout/3069 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


This report studies the global High Throughput Process Development market, analyzes and researches the High Throughput Process Development development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Market segment by Type, High Throughput Process Development can be split into Instrument Software and Service Market segment by Application, High Throughput Process Development can be split into Monoclonal Antibodies Recombinant Insulin Global High Throughput Process Development Market Size, Status and Forecast 2022 1 Industry Overview of High Throughput Process Development 1.1 High Throughput Process Development Market Overview 1.1.1 High Throughput Process Development Product Scope 1.1.2 Market Status and Outlook 1.2 Global High Throughput Process Development Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 High Throughput Process Development Market by Type 1.3.1 Instrument 1.3.2 Software and Service 1.4 High Throughput Process Development Market by End Users/Application 1.4.1 Monoclonal Antibodies 1.4.2 Recombinant Insulin 2 Global High Throughput Process Development Competition Analysis by Players 2.1 High Throughput Process Development Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 Danaher Corporation 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 GE Healthcare 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 Agilent Technologies 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.3.5 Recent Developments 3.4 Merck Millipore 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.4.5 Recent Developments 3.5 Thermo Fisher Scientific 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.5.5 Recent Developments 3.6 Bio-Rad Laboratories 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.6.5 Recent Developments 3.7 Eppendorf AG 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.7.5 Recent Developments 3.8 Perkinelmer, Inc 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.8.5 Recent Developments 3.9 Sartorius Stedim Biotech 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.9.5 Recent Developments 3.10 Tecan Group Ltd. 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 High Throughput Process Development Revenue (Value) (2012-2017) 3.10.5 Recent Developments 4 Global High Throughput Process Development Market Size by Type and Application (2012-2017) 4.1 Global High Throughput Process Development Market Size by Type (2012-2017) 4.2 Global High Throughput Process Development Market Size by Application (2012-2017) 4.3 Potential Application of High Throughput Process Development in Future 4.4 Top Consumer/End Users of High Throughput Process Development For more information, please visit https://www.wiseguyreports.com/sample-request/1206536-global-high-throughput-process-development-market-size-status-and-forecast-2022


News Article | May 8, 2017
Site: www.prnewswire.com

Laurie Brlas, Perrigo's Chairman, commented, "The additions of Adriana and Rolf to the Perrigo Board further enable us to enhance shareholder value. Their experiences and industry expertise add relevant perspectives as we continue to deliver on our strategic initiatives. On behalf of the Perrigo Board and management team, I want to thank Ellen for her dedication to Perrigo and its shareholders throughout her service." Jeffrey Smith, Starboard's CEO and Chief Investment Officer, said, "Together, the Board and management team continue to make progress on a number of key initiatives. Adriana and Rolf add valuable expertise to this newly constituted Board, which continues to focus on increasing shareholder value." Rolf A. Classon has extensive experience as a senior executive and Board member of a number of international medical device, biotechnology and pharmaceutical companies. He currently serves as Chairman of the Board of Directors at Tecan Group Ltd. and is on the Boards of Catalent, Inc., Fresenius Medical Care AG and Co. and Hill-Rom Holdings, Inc. Mr. Classon has served on a number of other Boards, including Auxilium Pharmaceuticals, Millipore Corporation, and Prometheus Laboratories Inc. He was Chairman of the Executive Committee and CEO for Bayer Healthcare from 2002 to 2004, in addition to holding a number of different positions at Bayer AG between 1991 and 2002. From 2005 to 2006 he served as interim President and CEO at Hillenbrand Industries, and prior to 1991 he held a number of different management positions at Pharmacia Corporation. Rolf will join Perrigo's Nominating and Governance Committee. Adriana Karaboutis currently serves as an independent director on several company Boards including Advance Auto Parts, Inc. and Blue Cross Blue Shield of Massachusetts. Previously, Adriana served as the Executive Vice President, Technology and Business Solutions at Biogen, Inc., where she oversaw information technology and led the digital health technology and advanced analytics team. Prior to her time at Biogen, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., and spent over 20 years at General Motors and Ford Company in various international leadership positions. Adriana will join Perrigo's Audit Committee. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is the world's largest manufacturer of over-the-counter ("OTC") healthcare products and supplier of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including the time, effort and expense to complete the restatement of its financial statements, future impairment charges, the ability to achieve its guidance, the completion of announced acquisitions or dispositions, the ability to execute and achieve the desired benefits of announced initiatives, and the timing, amount and cost of any share repurchases. In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting, may encounter unanticipated material issues or additional adjustments that could delay the completion of the restatement of its financial statements or the filing of required periodic reports with the SEC, or may be unable to regain compliance with the NYSE continued listing rules. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of the restatement of the Company's financial statements or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/perrigo-announces-two-new-independent-directors-300453069.html


Research and Markets has announced the addition of the "Global Drug Discovery Technologies Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Drug Discovery Technologies Market is poised to grow at a CAGR of around 12.2% over the next decade to reach approximately $160 billion by 2025. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. Some of the prominent trends that the market is witnessing include growing identification of combinatorial chemistry technology, regulatory initiatives fostering demand for pharmacogenomics technology, proteomics in anticancer drug discovery and human protein microarray for various protein analysis. Based on technology the market is categorized into pharmacogenomics, high throughput screening, genomics, bioinformatics, biochips, bioanalytical Instruments, nanotechnology, metabolomics and other technologies. Depending on the end users the market is segmented by research institutes, pharmaceutical companies, biotech companies, biopharmaceutical companies and other end users. Depending on the Applications the market is segmented by cardiovascular diseases, cancer Parkinson's disease, central nervous system disorders and other applications. - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments 3 Market Overview 3.1 Current Trends 3.1.1 Growing identification of combinatorial chemistry technology 3.1.2 Regulatory initiatives fostering demand for pharmacogenomics technology 3.1.3 Proteomics in anticancer drug discovery 3.1.4 Human protein microarray for various protein analysis 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 4 Drug Discovery Technologies Market, By Technology Type 4.1 Pharmacogenomics 4.2 High Throughput Screening 4.3 Genomics 4.3.1.1 Structural Genomics 4.3.1.2 Functional Genomics 4.3.1.3 Other Genomics technologies 4.3.1.3.1.1 Clinical Medicine 4.3.1.3.1.2 New Antibiotics 4.4 Bioinformatics 4.4.1.1 Computer-Aided Drug Design 4.5 Biochips 4.5.1.1 Lab on a chip 4.5.1.2 Proteomics microarrays 4.5.1.3 DNA and Protein microarrays 4.6 Bioanalytical Instruments 4.6.1.1 Chemotherapy instruments 4.6.1.2 Mass spectrometry 4.6.1.3 Microplate readers 4.6.1.4 Nuclear magnetic resonance 4.7 Nanotechnology 4.7.1.1 Nano-mass spectroscopy 4.7.1.2 Dip-pen Nanolithography 4.7.1.3 Atomic force microscopy (AFM) 4.8 Metabolomics 4.8.1.1 Target Identification 4.8.1.2 Target Validation 4.8.1.3 Lead Optimization 4.8.1.4 Mode of Action 4.8.1.5 Preclinical Studies 4.8.1.6 Clinical Studies 4.8.1.7 Post-Approval Studies 4.8.1.8 Diagnostics 4.9 Other Technologies 4.9.1.1 RNAi (RNA interference) 4.9.1.1.1.1 MiRNAS (MicroRNA sequencing) 4.9.1.1.1.2 SiRNA (Small interfering RNA) 4.9.1.1.1.3 Other RNAi technologies 4.9.1.2 Combinatorial chemistry 4.9.1.2.1.1 Chemical Encoding 4.9.1.2.1.2 Positional Encoding 4.9.1.2.1.3 Electronic Encoding 4.9.1.3 Synthetic Biology 4.9.1.4 Proteomic 4.9.1.4.1.1 Two dimensional gel electrphoresis- 2DGE 4.9.1.4.1.2 Two-hybrid systems 4.9.1.5 Cell Based Assays 4.9.1.6 Epigenetics 4.9.1.7 Systems Biology 4.9.1.7.1.1 Computer Modelling 4.9.1.8 Quantitative polymerase chain reaction (QPCR) 4.9.1.9 Laboratory information management systems 4.9.1.10 Microfluidics 4.9.1.11 Chromatography 4.9.1.12 Protein and nucleic acid isolation 6 Drug Discovery Technologies Market, By Application 6.1 Cardiovascular Diseases 6.2 Cancer 6.3 Parkinson's disease 6.4 Central Nervous System Disorders 6.5 Other Applications 6.5.1 Other Applications Market Forecast to 2025 (US$ MN) 7 Drug Discovery Technologies Market, By Geography - Affymetrix Inc. - Tecan Group Ltd. - Sigma-Aldrich Corp - Shimadzu Corp - Perkinelmer Inc. - Thermo Fisher Scientific Inc. - Incyte Corp - Gyros AB - F. Hoffmann-La Roche Ltd. - Evotec AG - Chembridge Corp - Abbott Laboratories Inc. - Celera Corp - Caliper Life Sciences Inc. - Bio-Rad Laboratories Inc. - Astrazeneca Plc. - Albany Molecular Research Inc. - Agilent Technologies Inc. - Charles River Laboratories International Inc. - Life Technologies Corp For more information about this report visit http://www.researchandmarkets.com/research/n5klng/global_drug


News Article | December 13, 2016
Site: marketersmedia.com

Wiseguyreports.Com Adds “Medical Automation -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database According to Stratistics MRC, the Global Medical Automation Technologies Market is estimated to be $52.67 billion in 2015 and is expected to reach $95.2 billion growing at a CAGR of 8.8%. The factors that are influencing the market growth include rising healthcare costs, investment by venture capitalists and the increase in use of point of care testing devices (glucose meters, digital blood pressure monitors, pregnancy test kits and HIV test kits). However the tax imposed by the U.S government on medical devices manufacturers and rigorous approval procedures to launch a product or services by companies is likely to hinder the market growth. North America is anticipated to hold the largest market share, followed by Europe. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Increasing aged population, growing occurrence of CVDs, diabetes, and cancer, increased funding on healthcare and life sciences research are propelling the growth of the Asia-Pacific market. Furthermore, the rising need of automation in various other medical fields represents the growth opportunities for this market. Some of the major players in the Global Medical Automation Technologies Market include GE Healthcare, Philips Healthcare, Siemens Healthcare, Tecan Group Ltd., Stanley Black and Decker, Inc., Intuitive Surgical, Inc., CAE Ltd., Brainlab AG, Given Imaging Ltd. and Medtronic, Inc. Applications Covered: • Therapeutic Automation • Lab and Pharmacy Automation • Logistics and Training Automation • Diagnostics and Monitoring Automation End Users Covered: • Research Labs and Institutes • Hospitals and Diagnostic Centers • Pharmacies • Home/Ambulatory and Others Type of Technologies Covered: • Robotic and computer-assisted surgical equipment o Surgical robots o Surgical planners and simulators o Intelligent operating rooms and related equipment o Surgical navigation systems • Automated therapeutic (non-surgical) devices o Automated medication delivery systems o Automated defibrillators • Automated prescription fulfillment devices o Dispensing machines o Intravenous compounders o Packaging machines • Automated medical imaging and image analysis o Automated microscopy o Automated radiography and fluoroscopy o Automated skin cancer detection o Automated whole-breast ultrasound o Computer-aided detection o Endoscopic capsules • Automated laboratory testing and analysis o Point-of-care Testing Systems o Central Laboratory Systems • Automated healthcare logistics, resource and patient tracking o Hospital asset/patient/staff tracking systems o Automated hospital pickup and delivery • Automated health assessment and monitoring technologies o Wearable monitors o Telehealth kiosks o Automated home monitoring and telemetry o Automated eye examination devices o Automated drug testing Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/649650-medical-automation-global-market-outlook-2016-2022


News Article | December 5, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Medical Automation Technologies Market is estimated to be $52.67 billion in 2015 and is expected to reach $95.2 billion growing at a CAGR of 8.8%. The factors that are influencing the market growth include rising healthcare costs, investment by venture capitalists and the increase in use of point of care testing devices (glucose meters, digital blood pressure monitors, pregnancy test kits and HIV test kits). However the tax imposed by the U.S government on medical devices manufacturers and rigorous approval procedures to launch a product or services by companies is likely to hinder the market growth. North America is anticipated to hold the largest market share, followed by Europe. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Increasing aged population, growing occurrence of CVDs, diabetes, and cancer, increased funding on healthcare and life sciences research are propelling the growth of the Asia-Pacific market. Furthermore, the rising need of automation in various other medical fields represents the growth opportunities for this market. Some of the major players in the Global Medical Automation Technologies Market include GE Healthcare, Philips Healthcare, Siemens Healthcare, Tecan Group Ltd., Stanley Black and Decker, Inc., Intuitive Surgical, Inc., CAE Ltd., Brainlab AG, Given Imaging Ltd. and Medtronic, Inc. Applications Covered: • Therapeutic Automation • Lab and Pharmacy Automation • Logistics and Training Automation • Diagnostics and Monitoring Automation End Users Covered: • Research Labs and Institutes • Hospitals and Diagnostic Centers • Pharmacies • Home/Ambulatory and Others Type of Technologies Covered: • Robotic and computer-assisted surgical equipment o Surgical robots o Surgical planners and simulators o Intelligent operating rooms and related equipment o Surgical navigation systems • Automated therapeutic (non-surgical) devices o Automated medication delivery systems o Automated defibrillators • Automated prescription fulfillment devices o Dispensing machines o Intravenous compounders o Packaging machines • Automated medical imaging and image analysis o Automated microscopy o Automated radiography and fluoroscopy o Automated skin cancer detection o Automated whole-breast ultrasound o Computer-aided detection o Endoscopic capsules • Automated laboratory testing and analysis o Point-of-care Testing Systems o Central Laboratory Systems • Automated healthcare logistics, resource and patient tracking o Hospital asset/patient/staff tracking systems o Automated hospital pickup and delivery • Automated health assessment and monitoring technologies o Wearable monitors o Telehealth kiosks o Automated home monitoring and telemetry o Automated eye examination devices o Automated drug testing Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific       • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


— The report "Lab Automation Market by Equipment & Software (Robotic Arm, Microplate Readers, LIMS), Applications (Drug Discovery, Clinical Diagnostics), Type (Modular, Total Lab), & End Users (Biotechnology & Pharmaceuticals, Private Labs) - Global Forecasts to 2021" , provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue. The global lab automation market is projected to reach USD 5.48 Billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 6.9% from 2016 to 2021. Factors such as miniaturization of processes resulting in low reagent costs and high productivity, progressing drug discovery and clinical diagnostics, benefits of lab automation over traditional laboratory settings, government funding for biotech and drug discovery research, and shortage of laboratory professionals are the key drivers for the growth of the global lab automation market. On the other hand, lack of planning for technology development, low priority for lab automation among small and medium-sized laboratories, and indefinite data interchange/communication standards are the major factors that are restraining the growth of the lab automation market. High potential emerging markets such as China, Japan, and Middle East represents significant growth opportunities for the key players in the lab automation market. Further, the concern for reluctance to move from manual operations towards automation and lack of compatibility between systems across a laboratory may pose challenges to the growth of this market during the forecast period. The global lab automation market is segmented on the basis of equipment and software, applications, type, end users, and regions. By equipment and software, the market is categorized into automated liquid handling, microplate readers, software & informatics, standalone robots, automated storage & retrieval systems (ASRS), and other equipment & software. The automated liquid handling segment is expected to account for the largest share of the lab automation market in 2016. This large share can be attributed to the high demand for automation in liquid handling. On the basis of application the lab automation market is segmented into drug discovery, clinical diagnostics, genomics solutions, proteomics solutions, and other applications. The drug discovery application segment is expected to account for the largest share of the global lab automation market in 2016. This large share can be attributed to the need for high-/ultra-high-throughput screening and reduced time-to-market for drugs. North America is expected to account for the largest share of the lab automation market in 2016. This region is estimated to account for the largest share of the tangential flow filtration market. In this region the increase in aging population, rising prevalence of lifestyle diseases, economy stimulus programs are driving the growth of the market. However, Asian countries are expected to witness a higher growth rate. Factors such as increasing healthcare investments, large population, improving public health awareness (leading to preventative care and hence more diagnostic tests), and rising demand for standardization and accreditation are creating significant growth for the lab automation market in Asia. Major players operating in the lab automation market are Tecan Group Ltd. (Switzerland), PerkinElmer Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), and Danaher Corporation (U.S.). For more information, please visit http://www.marketsandmarkets.com/Market-Reports/lab-automation-market-1158.html


News Article | November 24, 2016
Site: www.prnewswire.co.uk

According to a new market research report "High-Throughput Screening Market by Technology (Cell-based Assays (2D & 3D Cell Culture), Lab-on-a-chip, Bioinformatics), Application (Target Identification, Primary Screening, Toxicology), Product (Reagent & Instruments), End User - Forecast to 2021", published by MarketsandMarkets, the global market is expected to reach USD 18.83 Billion by 2021 from USD 12.23 Billion in 2016, at a CAGR of 7.8% from 2016 to 2021. Browse 237 market data Tables and 39 Figures spread through 252 Pages and in-depth TOC on "High-Throughput Screening Market" Early buyers will receive 10% customization on this report. The major factors driving the growth of this market include growing adoption of open innovative models in pharmaceutical and biotechnology companies and increasing R&D spending. Technological advancements in the HTS technique & rising government funding are some other factors driving the growth of this market. Emerging markets and growing research activities in toxicology and stem cells are expected to provide further growth opportunities for players operating in the market. Label-free technology and automation and miniaturization of HTS techniques are the key trends of this market. However, the high cost and time-consuming nature of HTS techniques are restraining the growth of this market during the forecast period. This market is segmented on the basis of product and service, technology, application end user and regions. Based on product and service, the global High-Throughput Screening Market is segmented into consumables and reagents, instruments, & software and services. In 2015, consumables and reagents accounted for the largest share of the global high-throughput screening products and services market. The availability of a wide range of reagents and continual product developments and innovations contributes to their largest share in HTS products and services market. Furthermore, on the basis of end users, the market is classified into pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs) and other end users. The other end users segment includes hospitals & clinics, and food, agriculture, and environmental industries. The pharmaceutical and biotechnology companies segment accounted for the largest share in the global HTS market, by end users. The extensive use of the HTS technology in pharmaceutical and biotechnology companies for drug discovery applications is the major factor driving the growth of this market. In 2015, North America accounted for the largest share of the global High-Throughput Screening Market, followed by Europe, Asia-Pacific, and RoW. Growth in the developed markets in North America and Europe is mainly driven by the large spending on pharmaceutical R&D and high adoption of HTS and availability of government funding, and the presence of major companies in this region. However, Asia-Pacific and Latin American regions provide wide scope for the High-Throughput Screening Market growth. This is mainly attributed to the increasing R&D spending; growing trend of outsourcing drug discovery services; growing public-private partnerships; and increasing government funding. Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), PerkinElmer, Inc. (U.S.) and Tecan Group Ltd. (Switzerland)held the major share of the High-Throughput Screening Market and will continue to dominate the market between 2016 and 2021. Other major players operating in this market are Merck Millipore (U.S.), Bio-Rad laboratories (U.S.), Hamilton Company (U.S.), Axxam S.p.A. (Italy) and Aurora Biomed (Canada). 3D CELL CULTURE MARKET by Technology (Scaffold Based, Scaffold Free), Application (Cancer Cell Research, Cell-based Assays/Toxicity Screening), End-Users (Biotechnology & Pharmaceuticals Industries) and Geography- Global Forecast to 2021. MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | December 9, 2016
Site: marketersmedia.com

— This report studies the global Medical Automation Technologies market, analyzes and researches the Medical Automation Technologies development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GE Healthcare Philips Healthcare Siemens Healthcare Tecan Group Ltd Stanley Black and Decker Intuitive Surgical CAE Ltd Brainlab AG Given Imaging Ltd Medtronic Awarepoint Corp Asahi Kasei CareFusion Roche Holding AG For more information or any query mail at sales@wiseguyreports.com Market segment by Application, Medical Automation Technologies can be split into Application 1 Application 2 Application 3 1 Industry Overview of Medical Automation Technologies 1.1 Medical Automation Technologies Market Overview 1.1.1 Medical Automation Technologies Product Scope 1.1.2 Market Status and Outlook 1.2 Global Medical Automation Technologies Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Medical Automation Technologies Market by End Users/Application 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 2 Global Medical Automation Technologies Competition Analysis by Players 2.1 Medical Automation Technologies Market Size (Value) by Players (2015-2016) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 GE Healthcare 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.1.5 Recent Developments 3.2 Philips Healthcare 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.2.5 Recent Developments 3.3 Siemens Healthcare 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.3.5 Recent Developments 3.4 Tecan Group Ltd 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.4.5 Recent Developments 3.5 Stanley Black and Decker 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.5.5 Recent Developments 3.6 Intuitive Surgical 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.6.5 Recent Developments 3.7 CAE Ltd 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.7.5 Recent Developments 3.8 Brainlab AG 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.8.5 Recent Developments 3.9 Given Imaging Ltd 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.9.5 Recent Developments 3.10 Medtronic 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Medical Automation Technologies Revenue (Value) (2011-2016) 3.10.5 Recent Developments 3.11 Awarepoint Corp 3.12 Asahi Kasei 3.13 CareFusion 3.14 Roche Holding AG For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com

Loading Tecan Group Ltd collaborators
Loading Tecan Group Ltd collaborators